George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Is my message to all invested. CTA has not been rejected. That would see us 50% down or more. It’s a clerical issue that can, and should be resolved. I still believe we have a world beating compound. This simply delays proceedings by up to another 60 days.
The bod have held their hands up and said they’re not precisely sure what the issue is, and I’m sure they will tell us and rectify just as soon as they know themselves.
Yea the SP will dip as it’s a good opportunity to release capital for the traders for a little while longer until CTA resubmission anticipation hots up again.
I’ll be holding and possibly topping up - for me this has always been win or bust. It’ll either work and be 10x or it won’t, and it’ll be £0.00. Somewhere between that is the option of an early stage takeover which would be higher than the current SP so either way…
Good luck, don’t listen to me; take your own advice - but don’t panic sell out at the bottom of the dip. I can imagine there will be some heavy buying after the first hour.
Sounds like it’s not a formal notification as yet, and hopefully just because they require further clarification on some points of the submission, and have to either approve or reject within certain timeframes.
Once SAR know more I’m sure they will detail to us and reassure, then resubmit. Just delays things a little :(
Aber, I wouldn’t worry yourself about the % uplift - that’s derived from the deal price and not driving the deal.
No company ever says “I’ll buy you for 50% above your share price”. They agree the deal in £££ based on what it’s worth to them over the forecast shelf life and returns of the product.
I have literally no idea. All I am confident in is that it will be above ATH as I believe in the science.
A bit like asking “what will Apple be worth in the future?” No idea, but if you believe in the company and that your investment will provide a decent return, you hold.
Thanks WIP :)
Yep agree we won’t ever take our bits to P3 but that doesn’t mean we aren’t worth anything yet. Just didn’t want people to think “Sierra got nearly $2bn from big pharma” and comparing apples with pears.
I’m more in the mindset that mid pharma will buy either our compounds or us entirely and take them to p3 then sell on, rather than direct big pharma take over.
Without putting a dampener on this weeks fantastic momentum, I just wanted to try and level some expectations around a potential SAR buyout and price.
Momelotinib I believe is the main reason for GSK’s buy out. That recently completed and showed positive results for Phase 3 trials. We are a long way from phase 3.
I’m excited; 737 in GSK’s possession is a great place to be for us too.
However, this to me shows that big pharma would rather let the small guys take the risks and get through trials, before going deep into their pockets. If anyone were to acquire us at this stage, it would be for a fraction of what we would be worth after Phase 3.
Been holding here for a good while, love the science and will continue to hold for as long as necessary; I’m just not expecting a sale RNS overnight.
I think we are all agree this won’t be an overnight 50% or 100% increase. We mostly agree this is a good long term investment.
There are perceived “bargains” to be had in the market given the last few weeks, people will be searching into which other investments they can sell in order to capitalise on these perceived bargains.
Other shares take bigger hits, people look to their slow burners to release some capital to chuck into bargain. We will take a knock on hit as a result.
Not saying C isn’t having an impact, but look at the bigger picture.
Still holding solid here; firm back burner but when that fire ignites, I’ll be a happy man.
Rose dramatically are the Federal Agency for Subsoil Use.
TPI contains Applications for geological study of subsoil.
*someone* has applied for a larger area for Trivanya, north of MT flanks.
That someone is most likely us, given the location.
Yes it is something to be excited about, particularly if granted.
Nothing to do with JORC yet.
I find the sentiment quite funny really.
Everyone was losing their minds when PH were appointed on the fact it was just PH, suggesting they were going to bring in massive IIs or a big sale etc etc.
If anyone did any research about what PH actually do, there were numerous outcomes not limited to:
Placings
Acquisitions
Market makers (oooohhhh baddies! /sarcasm)
Consolidations
People chose their own narrative, and now the same people are throwing tomatoes at PH.
Consolidation in the above example makes ZERO difference.
Let’s say I own 1000 shares in SAR at 20p. £200
£17 per share GSK = 11.76 GSK shares in a swop. 85 SAR for 1 GSK.
Consolidate 100:1. I now have 10 SAR shares at £20. Total value £200.
Oh look. 11.76 GSK shares. Just at 0.85:1. Which is 85/100 aka consolidation.
Not sure anyone has actually read the OP properly ?
He semi clearly stated dumping more cash INTO the share. Ie. Buying more.
Dump probably wasn’t the right word to use as “dump” usually infers selling stock you hold.
@pot
I see the science is the business model. We aren’t researching anything new. We are taking existing compounds to the relevant approval phases.
Add each compound and approval phase to a timeline and that is the business model, that ultimately will end in a £ per treatment * forecast treatments annually and thus annual revenue, which will be reflected handsomely in the SP.
^ that is years away, being truthful.
One objective may be to sell a compound/the entire company to big pharma and let them develop to production, which will expedite the payout timelines for us share holders, but that isn’t a business model.
The science can still be unsuccessful.